Psyence Biomedical Ltd Common Shares

Yahoo Finance • last month

Trump Trade: President to sign order on psychedelic used for PTSD

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly. Claim 30% Off TipRanks Unlock hed... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs,... Full story

Yahoo Finance • 3 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs,... Full story

Yahoo Finance • 5 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs,... Full story

Yahoo Finance • 6 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs,... Full story

Yahoo Finance • 9 months ago

Unusual volume stocks in Monday's session

Unusual volume stocks are being observed in Monday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/profile] 76.28% PSYENCE BIOMEDICAL LTD (NASDAQ:P... Full story

Yahoo Finance • 9 months ago

Corporate Update, August 2025

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived p... Full story

Yahoo Finance • 10 months ago

Psyence Biomedical stock soars after partner achieves ibogaine breakthrough

Investing.com -- Psyence Biomedical Ltd. (NASDAQ:PBM) stock surged 70% after the company announced that its strategic partner, PsyLabs, successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all m... Full story

Yahoo Finance • 10 months ago

PsyLabs produces GMP-aligned ibogaine extract, meeting safety standards

NEW YORK - Psyence Biomedical Ltd. (NASDAQ:PBM), a micro-cap biotech company with a market capitalization of $3.15 million, announced Thursday that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkalo... Full story

Yahoo Finance • 10 months ago

Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compoun... Full story

Yahoo Finance • 11 months ago

Psyence Biomedical regains Nasdaq compliance after reverse split

NEW YORK - Psyence Biomedical Ltd. (NASDAQ: PBM), currently trading at $4.37 with a market capitalization of $2.55 million, has regained compliance with all Nasdaq continued listing requirements following a hearing on May 29, the company a... Full story

Yahoo Finance • last year

Psyence Group Announces Share Consolidation

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares") on the... Full story

Yahoo Finance • last year

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced tha... Full story

Yahoo Finance • last year

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced tha... Full story